Published: December 09, 2012
Press Release
Active Biotech and Ipsen Announce Completion of Recruitment of Tasquinimod Clinical Phase III Study in Prostate Cancer
LUND, Sweden & PARIS - (BUSINESS WIRE) - Regulatory News:
Active Biotech (NASDAQ OMX NORDIC: ACTI) and Ipsen (Paris:IPN)
(Euronext: IPN; ADR: IPSEY) today announced that the Phase III clinical
trial for tasquinimod, a novel compound for the treatment of prostate
cancer, is successfully enrolled with over 1,200 randomized patients as
planned in the clinical protocol. This achievement triggers a €10
million milestone payment from Ipsen to Active Biotech.
This study is a global, pivotal, randomized, double-blind,
placebo-controlled Phase III clinical trial of tasquinimod in patients
with metastatic castrate resistant prostate cancer (mCRPC). The aim of
the study is to confirm tasquinimod's efficacy, with radiological
Progression Free Survival (PFS) as primary endpoint and overall survival
(OS) as secondary endpoint. The study recruited patients in more than
250 centers all over the word.
To read the complete release at NewsBlaze,
Active Biotech and Ipsen Announce Completion of Recruitment of Tasquinimod Clinical Phase III Study in Prostate Cancer,
Click here
Related Business Wire News
ACE receives regulatory approval for Myanmar representative office
Chemtura Corporation today announced that Stephen Forsyth, executive vice president and chief financial officer, and Dalip Puri, vice president of investor relations and treasurer, will present at the Credit Suisse Basic Materials Conference from 8 ...
Signet Interactive, LLC, a Houston-based leader of interactive marketing and media services, received top honors in the 27th Annual Crystal Awards in the categories of Website, Healthcare and Website, Small Budget for their marketing excellence ...
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC announce that KSF has commenced an investigation into the Board of Directors of rue21, Inc. in connection with their conduct related to ...
Samson Oil & Gas Limited advises that the closing date, being the last day for acceptances and payments for the current non renounceable rights offer, for holders of American Depositary Shares in the USA will occur at 5.00 pm New York time on ...
The Securities Arbitration Law Firm of Klayman & Toskes, P.A. announced today that it is investigating potential claims against Ameriprise Financial and LPL Financial surrounding allegations of misconduct by former Ameriprise Advisor Services ...
